¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Glial Cell Line-Derived Neurotrophic Factor Receptors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î¼º
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷, Á߽ɼ±¹æ¼¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷, ģũ·Ò¼¼Æ÷
  • chromophilic cell
    »ö¼Òµê¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµê¼¼Æ÷
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • complex cell
    º¹ÇÕ¼¼Æ÷
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • continuous cell line
    ¹«ÇÑÁõ½Ä¼º¼¼Æ÷ÁÖ, ¿¬¼Ó°è´ë¼¼Æ÷ÁÖ
  • continuous cell separator
    ¿¬¼Ó¼¼Æ÷ºÐ¸®±â
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
  • crenated cell
    Åé´ÏÀûÇ÷±¸
  • crypt cell
    âÀÚ»ù¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷, ÁÖ»çÀ§¼¼Æ÷
  • cylindrical cell
    (¢¡columnar cell) ¿øÁÖ¼¼Æ÷
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹é
  • dark cell
    ¾îµÒ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • Tzanck cell
    Á¤Å© ¼¼Æ÷
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • accessory cell
    º¸Á¶¼¼Æ÷, ºÎ¼ö¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    ¼±Æ÷ ¼¼Æ÷(àÍøàá¬øà)
  • acinar cell
    ¼±¹æ¼¼Æ÷(¡­á¬øà)
  • acinic cell carcinoma
    ¼±¹æ¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adult T Cell leukemia virus
    ¼ºÀÎ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult T cell leukemia virus (HTLV)
    ¼ºÀÎT¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • hageman factor
    ÇϰԸ¸ ÀÎÀÚ, Hageman ÀÎÀÚ
  • hematopoietic growth factor
    Á¶Ç÷¼ºÀåÀÎÀÚ
  • hemorrhagic diathesis,clotting factor abnormalities
    ÀÀ°íÀÎÀÚ ÀÌ»ó
  • hepatocyte growth factor
    °£¼¼Æ÷¼ºÀåÀÎÀÚ
  • histamine sensitizing factor =HSF
    È÷½ºÅ¸¹Î°¨ÀÛÀÎÀÚ(¡­ÊïíÂì×í­).
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • host factor
    ¼÷ÁÖÀÎÀÚ
  • host integration factor (HIF)
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • hunter blood factor
    ÇåÅÍÇ÷¾×ÀÎÀÚ(?Ì´Ëâ ËöËö).
  • hunter blood factor
    ÇåÅÍÇ÷¾×ÀÎÀÚ(¡­úìäû ì×í­).
  • hyperglycemic glycogenolytic factor
    °íÇ÷´ç¼º ´ç¿øºÐÇØ(¼º) ÀÎÀÚ.
  • hypothalamic releasing factor
    ½Ã»óÇϺιæÃâÀÎÀÚ.
  • hypothalamic releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ(ë¤×ãì×í­).
  • hypothalamus releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ.
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • pyruvate oxidation factor
    ÆÄÀÌ·çºê»ê(ß«) »êÈ­ÀÎÀÚ(ß«ûùì×í­)
  • rat antispectacle eye factor
    Áã Ç׾ȱ¸ µ¹ÃâÁõ ÀÎÀÚ(ù÷äÑϹÔÍõóñøì×í­)
  • recruitment factor
    º¸ÃæÀÎÀÚ(ÜÍõöì×í­)
  • regulatory factor
    Á¶Àý ÀÎÀÚ(ðàï½ì×í­)
  • Reid factor
    ¶óÀ̵å ÀÎÀÚ(ì×í­)
  • relaxing factor
    ÀÌ¿Ï ÀÎÀÚ(ì¬èÐì×í­)
  • release factor
    À¯¸® ÀÎÀÚ(ë´×îì×í­)
  • resistance factor
    ÀúÇ× ÀÎÀÚ(ì×í­)
  • resistance-transfer factor
    ÀúÇ×ÀüÀÌ ÀÎÀÚ(ï®ì¹ì×í­)
  • R factor
    R ÀÎÀÚ(ì×í­)
  • Rhesus factor
    ·¹¼­½º ÀÎÀÚ(ì×í­)
  • rheumatoid factor
    ·ù¸¶ÅäÀ̵å ÀÎÀÚ
  • Rh factor
    Rh ÀÎÀÚ
  • rho factor
    rho ÀÎÀÚ
  • ribosome dissociating factor
    ¶óÀ̺¸¼Ø ÇØ¸®ÀÎÀÚ(ú°×îì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
DRF Daily Rating Form; daily replacement factor; Deafness Research Foundation; dose reduction factor
EDF eosinophil differentiation factor; erythroid differentiation factor; extradural fluid
EIF erythrocyte initiation factor; eukaryotic initiation factor
FF degree of fineness of abrasive particles; fat-free; father factor; fecal frequency; fertility factor...
GF gastric fistula; gastric fluid; germ-free; glass factor; glomerular filtration; gluten-free; grandfa...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
SDF Stromal cell- derived factor
SDF1 alpha Stromal cell-derived factor 1 alpha
SBF Suppressive B-cell factor
Tcf T Cell Factor
TCGF T Cell Growth Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell wall
    ¼¼Æ÷ º®
    µ¿ÀǾî=cell membrane.
  • cell wall inhibitor
    ¼¼Æ÷ º® ÇÕ¼º ¾ïÁ¦Á¦
  • cell wall teichoic acid
    ¼¼Æ÷ º® ŸÀÌÄÚ»ê
  • cell,hydropic degeneration
    ¼öÆ÷¼º º¯¼º
  • cell-mediated cytotoxicity
    ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
    Ç×ü ȤÀº lym
  • cell-mediated hypersensitivity
    ¼¼Æ÷ ¸Å°³¼º °ú¹ÎÁõ
    TuberculinÇü Çdz» ¹ÝÀÀÀ» ´ëÇ¥·Î ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀÇ ÇÑ ÇüÅÂ. Ç׿ø¿¡ ÀÇÇÏ¿© °¨ÀÛµÈ µ¿¹°ÀÇ Çdz»¿¡ ÀçÂ÷ Ç׿øÀ» ÁÖ»çÇÔÀ¸·Î½á ¼ö ½Ã°£À¸·ÎºÎÅÍ 36½Ã°£ ÈÄ¿¡ ¹ßÀû, °æ°áÀ» ¼ö¹Ý½ÃŰ´Â Á¾Ã¢ÀÌ ÁÖ»ç ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¹ÝÀÀÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¼º ¸é¿ª °áÇÌ ÁõÈıº
  • central giant cell
    °ñ³» °Å´ë ¼¼Æ÷
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • central pain transmission cell
    ÁßÃß¼º ÅëÁõ Àü´Þ ¼¼Æ÷, ÁßÃß µ¿Åë Àü´Þ ¼¼Æ÷
  • centroacinar cell
    ²Ê¸® Á᫐ ¼¼Æ÷, »ùÆ÷ Á᫐ ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
    ±¸°­ »óÇÇÀÇ Á¶Á÷ Ç¥º»¿¡¼­ ´Ù¸¥ »óÇÇ ¼¼Æ÷¿Í´Â ´Þ¸® ÇÙ ÁÖÀ§¿¡ Åõ¸íÇÑ Èı¤
  • clear cell acanthoma
    Åõ¸í ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • clear cell hidradenoma
    Åõ¸í ¼¼Æ÷ ÇѼ±Á¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
maise factor <molecular biology, plant biology> A naturally occurring cytokinin, originally isolated from maize seeds. Its riboside is also a cytokinin.
(18 Nov 1997)
vascular endothelial growth factor A growth factor that is responsible for the growth of blood vessels.
(12 Dec 1998)
mammotropic factor <protein> Pituitary lactogenic hormone (23 kD) Synthesised on endoplasmic reticulum bound ribosomes as preprolactin that has an N terminal signal peptide that is cleaved from the mature form. The conversion of preprolactin to prolactin has been much used as an assay for membrane insertion.
(18 Nov 1997)
G factor The single common variance or factor that is common to (i.e., empirically intercorrelates with) different intelligence tests (general).
A substance required for the growth of a specific organism.
(05 Mar 2000)
Castle's intrinsic factor A mucoprotein normally secreted by the epithelium of the stomach and that binds vitamin B12, the intrinsic factor/B12 complex is selectively absorbed by the distal ileum, though only the vitamin is taken into the cell.
(18 Nov 1997)
maturation factor <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism.
(27 Sep 1997)
maturation-promoting factor <enzyme> A protein kinase that drives both the mitotic and meiotic cycles in all eukaryotic organisms.
In meiosis it induces immature oocytes to undergo meiotic maturation. In mitosis it has a role in the G2/M phase transition. Once activated by cyclins, maturation-promoting factor directly phosphorylates some of the proteins involved in nuclear envelope breakdown, chromosome condensation, spindle assembly, and the degradation of cyclins.
The catalytic subunit of maturation-promoting factor is protein p34cdc2.
Acronym: MPF
(12 Dec 1998)
reflection factor <microscopy> The ratio of reflected light from a surface to the incident light. This is sometimes called the coefficient of reflection. Unless especially stated it takes into account both specular and diffuse reflection.
(05 Aug 1998)
cattell personality factor questionnaire Self report questionnaire which yields 16 scores on personality traits, such as reserved vs. Outgoing, humble vs. Assertive, etc.
(12 Dec 1998)
glass factor <chemical> Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor xii to xiia. Deficiency of factor xii, also called the hageman trait, leads to increased incidence of thromboembolic disease.
Chemical name: Blood-coagulation factor XII
(12 Dec 1998)
relaxation factor Substance presumably involved in the return of muscle fibrils to the resting state after nervous stimulation ceases, postulated to act by withdrawing Calcium from myosin-ATPase sites.
(05 Mar 2000)
release factor A component of the specialised transport system involved in the transport of cobalamin (vitamin B12) across the wall of the intestine. Dissociates the complex between cobalamin and the extracellular cobalamin binding glycoprotein known as intrinsic factor.
(18 Nov 1997)
vitamin B12 with intrinsic factor concentrate A combination of vitamin B12 with suitable preparations of the mucosa of the stomach or intestine of domestic animals used for food by humans.
(05 Mar 2000)
glucose tolerance factor A water-soluble complex containing chromium needed for normal glucose tolerance.
(05 Mar 2000)
resistance factor <molecular biology> A self-replicating fragment of nucleic acid that confers drug resistance and is transmitted from one bacterium to another via conjugation.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á